Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 4/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.58 |
| ▸ | IDO1 | P14902 | 2/20 | 0.54 |
| ▸ | SPHK2 | Q9NRA0 | 3/20 | 0.42 |
| ▸ | SPHK1 | Q9NYA1 | 3/20 | 0.42 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.42 |
| ▸ | MMP13 | P45452 | 1/20 | 0.42 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.39 |
| ▸ | MMP1 | P03956 | 1/20 | 0.39 |
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5544193 | 0.84 | MAOB (0.46) | MAOBMAOAIDO1ALOX5FFAR4 | |
| SCHEMBL5535257 | 0.83 | MAOB (0.45) | MAOBMAOAIDO1FFAR4 | |
| SCHEMBL27629438 | 0.81 | MAOB (0.44) | MAOBMAOAIDO1FFAR4 | |
| SCHEMBL12423202 | 0.81 | MAOB (0.68) | MAOBMAOAIDO1SPHK2SPHK1 | |
| SCHEMBL28756697 | 0.80 | MAOB (0.43) | MAOBMAOAIDO1FFAR4 | |
| SCHEMBL6331479 | 0.80 | MAOB (0.66) | MAOBMAOAIDO1SPHK2SPHK1 | |
| SCHEMBL13439800 | 0.78 | MAOB (0.63) | MAOBMAOAIDO1SPHK2SPHK1 | |
| SCHEMBL13462731 | 0.78 | MAOB (0.71) | MAOBMAOAIDO1SPHK2SPHK1 | |
| SCHEMBL5541550 | 0.78 | OPRM1 (0.44) | MAOBMAOAALOX5APSLC6A4FFAR1 | |
| SCHEMBL863430 | 0.77 | MAOB (0.60) | MAOBIDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1343768-A1 | ARYL AND AMINOARYL SUBSTITUTED SEROTONIN RECEPTOR AGONIST AND ANTAGONIST LIGANDS | Bristol-Myers Squibb Pharma Company (US) | 2003-09-17 | — | — | EP | claimed |
| WO-2002059082-A2 | ARYL AND AMINOARYL SUBSTITUTED SEROTONIN RECEPTOR AGONIST AND ANTAGONIST LIGANDS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-08-01 | — | — | WO | claimed |
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1343768-A1 | ARYL AND AMINOARYL SUBSTITUTED SEROTONIN RECEPTOR AGONIST AND ANTAGONIST LIGANDS | Bristol-Myers Squibb Pharma Company (US) | 2003-09-17 | — | — | EP | disclosed |
| WO-2002059082-A2 | ARYL AND AMINOARYL SUBSTITUTED SEROTONIN RECEPTOR AGONIST AND ANTAGONIST LIGANDS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-08-01 | — | — | WO | disclosed |
| EP-0745072-A1 | 4-AMINO DERIVATIVES OF 5-SUBSTITUTED MYCOPHENOLIC ACID | SYNTEX (U.S.A.) INC. (US) | 1996-12-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | MAOB 2140/4885MAOA 2885/4885IDO1 3181/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.